Medtronic and Pi-Cardia Collaboration for TAVR Innovation
Key Announcement:
Medtronic plc announced a strategic investment in Pi-Cardia Ltd., focusing on enhancing care for complex transcatheter aortic valve replacement (TAVR) procedures.
Details:
- Investment: Up to $80 million, with an option to acquire Pi-Cardia for up to $210 million based on milestone achievements.
- Product: Pi-Cardia’s ShortCut™ device, the first FDA-cleared technology for leaflet modification, aims to assist patients at risk of coronary obstruction during valve-in-valve TAVR.
- Clinical Success: Demonstrated successful leaflet splitting and favorable safety in pivotal trials.
Statements:
Jorie Soskin of Medtronic highlighted the investment as a commitment to innovative technologies for complex heart procedures. Erez Golan, CEO of Pi-Cardia, emphasized the partnership’s potential to advance leaflet modification in TAVR.
Broader Impact:
This collaboration aims to enhance Medtronic’s structural heart offerings and improve patient outcomes by addressing significant clinical challenges in TAVR.
For further information, visit the original PR Newswire article.
